Med Tech-related technology assessments and clinical guidelines from NICE in December 2021

18

Jan 2022

In December 2021, NICE published two Interventional Procedures Guidance (IPG):

  • Endobronchial nerve ablation for chronic obstructive pulmonary disease;
  • Transanal total mesorectal excision for rectal cancer.

IPG is developed for most of the novel interventional procedures entering the English market. The program focuses solely on clinical evidence. Recommendations may vary from "for research only" to "for use with standard arrangements for clinical governance, consent, and audit." Recommendations are not binding, although they are followed by providers and commissioners.

NICE made the following conclusions:

Medical Technologies Guidance (MTG) evaluates new, innovative medical devices and diagnostics. It looks at medical technologies that deliver treatment, like those implanted during surgical procedures, give greater independence to patients, or detect or monitor medical conditions.

In December 2021, NICE issued two new MTGs.

  • NICE recommended ClearGuard HD antimicrobial barrier caps for preventing catheter-related bloodstream infections in people with central venous catheters having hemodialysis. Data should be collected on any long-term effect of chlorhexidine exposure, particularly in children. Cost modeling shows that ClearGuard HD caps are likely to be cost-saving over one year compared with standard treatments due to the lower incidence rate and associated cost of treating catheter-related bloodstream infections. The estimated savings per person are £351- £1,096, depending on the comparator;
  • NICE concluded that Endo-SPONGE shows promise for treating low rectal anastomotic leakage. However, there is not enough good-quality evidence to support the case for routine adoption in the NHS. Further research is recommended to address uncertainties about the benefits of Endo-SPONGE.

The MedTech Innovation Briefings (MIBs) is the advice program of NICE for innovative technologies. It provides an overview of clinical effectiveness, safety, and cost. It does not offer formal guidance, and it, therefore, does not provide any recommendations.

One new MIBs published in December 2021 on FreeO2 automatic oxygen titration tool that automatically adjusts the oxygen flow rate required to maintain target oxygenation set by the clinician. FreeO2 operates on a closed-loop and continuously adjusts the flow rate administered between 0 and 20 l/min (with or without humidification) based on blood oxygen saturation (SpO2). That reduces the risks of complications relating to hypoxia and hyperoxia.

One new clinical guideline was published in December 2021 on pelvic floor dysfunction prevention and non-surgical management.

Five clinical guidelines were updated in December 2021:

See the full details for guidance here. and for MIBs here

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

26

Jan 2023

The updated German Uniform Evaluation Standard (EBM) catalog came into force on January 1, 2023. The EBM catalog (Einheitlicher Bewertungsmaßstab) regulates the reimbursement of services in the public outpatient sector in Germany and is updated once a quarter (four times a year). Among other changes, a new code for "zanadio" health app for follow-up and evaluation was introduced in the catalog.

Read more

25

Jan 2023

On December 31, 2022, the Decree defining the reimbursement of medical telemonitoring activities via the new framework was published in the Official Journal of the French Republic. The Decree determines the methods of evaluation of digital solutions, registration for reimbursement, modification of the registration conditions, removal and invoicing of medical telemonitoring activities, as well as the conditions for setting the reimbursement packages.

Read more

24

Jan 2023

In December 2022, NHS England launched a consultation on the preliminary 2023/25 NHS Payment Scheme, which is set for two years and will replace the National Tariff Payment System from April 2023. Two new cardiovascular categories (antibacterial envelope, mitral valve repair and replacement devices) are proposed for inclusion in the 2023/24 High Cost Device List (will be updated and reissued for 2024/25). The deadline for comments submission is January 27, 2023.

Read more

23

Jan 2023

On December 26, 2022, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by sickness funds.

Read more

20

Jan 2023

In December 2022, the National Institute for Health and Care Research (NIHR) in England released six MedTech-related reports in its Health Technology Assessment (HTA) Journal, which concerned laser therapy in diabetic macular oedema, EarlyCDT Lung blood test, video-assisted thoracoscopic or open lobectomy, urethral slings for stress urinary incontinence, placental growth factor (PlGF) and sFlt-1 tests, and photobiomodulation in the management of oral mucositis. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

Read more